Warning: The NCBI web site requires JavaScript to function. more...
Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
Arthritis Res Ther. 2005;7(6):R1348-59. Epub 2005 Sep 30.
Related citations
Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis.
Okamoto H, Yoshio T, Kaneko H, Yamanaka H.
Arthritis Rheum. 2010 Jan;62(1):82-92.
NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T, Hoshino M, Aoki K, Ohya K, Komano Y, Nanki T, Miyasaka N, Umezawa K.
Arthritis Res Ther. 2007;9(5):R97.
A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis.
Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, Hur GM, Lee SY, Chung MJ, Park JW, Lee SI, Park BH.
Arthritis Rheum. 2010 Aug;62(8):2313-21.
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
Clin Cancer Res. 2005 Feb 1;11(3):1287-93.
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S.
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4342-50.
Effect of nuclear factor-kappaB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis.
Okazaki Y, Sawada T, Nagatani K, Komagata Y, Inoue T, Muto S, Itai A, Yamamoto K.
J Rheumatol. 2005 Aug;32(8):1440-7.
Reduction of tumor necrosis factor induced nuclear factor-kappaB nuclear translocation and DNA binding by dexamethasone in human osteoarthritic synovial tissue explants.
Lehmann T, Murphy C, Zahra DG, Handel ML.
J Rheumatol. 2002 Apr;29(4):787-95.
Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
Urology. 2010 Apr;75(4):805-12. Epub 2010 Feb 13.
Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
Transplantation. 2006 Dec 27;82(12):1720-7.
Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes.
Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F, Sun L.
Rheumatology (Oxford). 2007 Jun;46(6):920-6. Epub 2007 Feb 21.
Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S.
Clin Cancer Res. 2004 Oct 15;10(20):6821-9.
A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Umezawa K, Horie R.
Int J Cancer. 2005 Mar 10;114(1):32-8.
DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
Int J Oncol. 2006 Sep;29(3):713-9.
Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation.
Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP.
Arthritis Res Ther. 2006;8(4):R86.
Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E, Umezawa K.
Biomed Pharmacother. 2006 Nov;60(9):578-86. Epub 2006 Sep 1.
Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S.
Endocrinology. 2008 Nov;149(11):5357-65. Epub 2008 Jul 24.
Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells.
Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi M, Honda S, Hirai Y, Hida A, Ida H, Migita K, Kawabe Y, Koji T, Furuichi I, Aoyagi T, Eguchi K.
Ann Rheum Dis. 2001 Jul;60(7):678-84.
Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts.
Zhang HG, Huang N, Liu D, Bilbao L, Zhang X, Yang P, Zhou T, Curiel DT, Mountz JD.
Arthritis Rheum. 2000 May;43(5):1094-105.
The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis.
Gerlag DM, Ransone L, Tak PP, Han Z, Palanki M, Barbosa MS, Boyle D, Manning AM, Firestein GS.
J Immunol. 2000 Aug 1;165(3):1652-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on